Silver Book Fact

One economic model predicts that if type 1 and type 2 diabetics had begun Captopril (a drug that controls blood pressure and delays the onset of kidney failure) treatment in 1995, the aggregate health care cost savings in 1999 would have been $189 million and in 2004 would have been $475 million-a present value cumulative cost savings of $2.4 billion for those 10 years.

Rodby, Roger A., Louise Firth, and Edmund J. Lewis. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy. Diabetes Care. 1996; 19(10): 1051-61. http://care.diabetesjournals.org/cgi/content/abstract/19/10/1051

Reference

Title
An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy
Publication
Diabetes Care
Publication Date
1996
Authors
Rodby, Roger A., Louise Firth, and Edmund J. Lewis
Volume & Issue
Volume 19, Issue 10
Pages
1051-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • In a community-based pharmaceutical care services program for 194 participants in 2001, mean A1c decreased at follow-ups, with more than 50% of patients demonstrating improvements at each interval (each year…  
  • Detecting and treating diabetic eye disease with laser therapy can reduce the development of severe vision loss by an estimated 50% to 60%.  
  • Every additional dollar spent on intensive blood glucose control for newly diagnosed type 2 diabetic patients has produced health gains valued at $3.77.  
  • Blood pressure control reduces the risk of heart disease or stroke among Americans with diabetes by 33-50%.  
  • A recent study conducted by the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) so clearly demonstrated that lifestyle interventions reduced the risk of developing type 2 diabetes…